… The objective of this study was to demonstrate the noninferiority of zoledronic acid treatment
compared with pamidronate in preventing SREs in patients with cancer-related bone lesions…

… of care for breast cancer patients with bone metastases. However, zoledronic acid has been
… more potent than pamidronate disodium with respect to inhibition of bone resorption without …

… in this study, there was a suggestion that zoledronic acid was in fact more effective than
pamidronate.39 Multiple event analysis demonstrated a 20% reduction in the risk …

… linked events (eg, surgery to repair a fracture) were not counted as separate events; this was
in line with the statistical methods of the trial comparing zoledronic acid versus pamidronate …

… of patients with bone metastases secondary to breast cancer. … that breast cancer patients
treated with 4 mg zoledronic acid … compared with patients in the pamidronate group (p = 0.037; …

… Zoledronic acid was effective in patients with multiple myeloma or metastatic breast cancer
with osteolytic or mixed bone … of treatment with zoledronic acid 4mg or pamidronic acid 90mg, …

… analyses in patients with breast cancer suggested that zoledronic acid therapy is cost …
Why is zoledronic acid superior to pamidronate for bone metastases from breast cancer but …

… In conclusion, denosumab was superior to zoledronic acid … to pamidronate. (2) The results
of step 1 were combined with the results of a trial comparing zoledronic acid with pamidronate …

… of age or above and who have at least one bone metastasis (… using pamidronate and
zoledronic acid in breast cancer … performed to identify the treatment strategy that achieves the …

… study and the other solid tumor study and was 90 mg of pamidronate (Pam) in the study of
breast cancer and multiple myeloma. Studies were amended twice because of renal toxicity, …